Finance

Lists
Q3 2026 earnings • in 5 days
See details
MGX:NASDAQ
Metagenomi Therapeutics Inc
$0.73
-7.49%
(-0.059) 1D
$0.72
-1.83% (-0.013)
After hours
Closed: Nov 5, 4:00:02 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for MGX...
Open
$0.78
High
$0.78
Low
$0.71
Mkt. cap
27.61M
Avg. vol.
152.66K
Volume
0.00
52-wk high
$2.28
52-wk low
$0.71
EPS
-$2.49
Shares outstanding
37.78M
No. of employees
113
Open
$0.78
High
$0.78
Low
$0.71
Mkt. cap
27.61M
Avg. vol.
152.66K
Volume
0.00
52-wk high
$2.28
52-wk low
$0.71
EPS
-$2.49
Shares outstanding
37.78M
No. of employees
113
News stories
From web sources and news partners
About Metagenomi Therapeutics Inc
CEO-
Employees113
Founded2016
HeadquartersEmeryville, California, United States
SectorHealth Care
IndustryBiotechnology
Websitemetagenomi.co
Analyst ratings
Based on 4 analysts giving stock ratings to MGX in the past 3 months
Strong buy
Buy
3
Hold
1
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for MGX in the last 3 months.
Highest
Current $0.73
$7.00 (+857.85%)
Average
$6.00 (+721.02%)
Lowest
$5.00 (+584.18%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
J.P. Morgan
Hold
Maintained
-
-
08/17/2026
Joseph Thome
TD Cowen
Buy
Maintained
-
-
08/11/2026
Yanan Zhu
Wells Fargo
Buy
Reiterated
$7.00
+857.9%
08/11/2026
Keay Nakae
Chardan Capital
Buy
Maintained
$5.00
+584.2%
08/10/2026
Geulah Livshits
Chardan Capital
Buy
Maintained
$5.00
+584.2%
07/07/2026
Next call in 5 days
Tue, Nov 10, 11:00 PM
Fiscal period
Q3 2026
- / -$0.62
Revenue / Est. (USD)
- / 2.06M
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
8.66M
3.91M
1.25M
-257.00K
Cost of goods sold
25.28M
21.50M
19.30M
22.51M
Cost of revenue
25.28M
21.50M
19.30M
22.51M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
6.22M
6.78M
6.54M
6.00M
Operating expense
6.22M
6.78M
6.54M
6.00M
Total operating expenses
31.50M
28.28M
25.84M
28.52M
Operating income
-22.84M
-24.37M
-24.59M
-28.77M
Other non operating income
-2.00K
-11.00K
-1.00K
35.00K
EBT including unusual items
-20.63M
-22.49M
-23.05M
-27.48M
EBT excluding unusual items
-20.63M
-22.49M
-23.05M
-27.48M
Income tax expense
-234.00K
34.00K
10.00K
-
Effective tax rate
1.13%
-0.15%
-0.04%
-
Other operating expenses
-
-
-
-
Net income
-20.39M
-22.53M
-23.06M
-27.48M
Net profit margin
-235.51%
-576.02%
-1,847.68%
10,693.39%
Earnings per share
-0.55
-0.60
-0.61
-0.73
Interest and investment income
2.21M
1.88M
1.54M
1.26M
Interest expense
-
-
-
-
Net interest expenses
2.21M
1.88M
1.54M
1.26M
Depreciation and amortization charges
-
-
-
-
EBITDA
-21.52M
-23.07M
-23.31M
-27.51M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps